Quick Facts at a Glance
- Recall Date
- July 9, 2025
- Hazard Level
- HIGH
- Brand
- Boothwyn Pharmacy
- Category
- Health & Personal Care
- Sold At
- Unknown
- Geographic Scope
- 1 states
- At-Risk Groups
- GENERAL, PREGNANT
What to Do Now
Use this page like a recall checklist: verify the product first, then act on the official remedy.
Immediate steps
- 1Stop using the product until you confirm whether it is included in the recall.
- 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
- 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
- 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.
Check these identifiers
- Brand
- Boothwyn Pharmacy
- Product type
- Semaglutide Injection
- Model numbers
- 03202025@5, 03202025@6, 03202025@7, 03202025@8 BUD 07/18/2025
- Sizes
- 2 mL vial
- Sold at
- Unknown
- Where affected
- ALL
Recall Timeline
Key dates and source checks for this recall record.
Recall announced
July 9, 2025
Reported by FDA DRUG
September 10, 2025
RecallRadar source check
April 18, 2026
Consumer action
Use the official remedy and keep documentation.
Hazard Information
Subpotent Drug
What You Should Do
Consumers and healthcare providers should stop using this product immediately. Contact Boothwyn Pharmacy LLC or your healthcare provider for guidance. Notification method: Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
About This Product
Semaglutide injections are used to improve glycemic control in type 2 diabetes and for weight management in obesity. They are prescribed and distributed through pharmacies.
Why This Is Dangerous
Subpotent drugs may provide insufficient therapeutic effect, risking poor disease management and complications.
Industry Context
This recall is not part of a broader industry pattern in the provided data.
Real-World Impact
Patients may require medical adjustment or replacement therapy to maintain therapeutic outcomes.
Practical Guidance
How to identify if yours is affected
- Verify quantity 642 vials and U.S. nationwide distribution.
- Cross-check with Boothwyn Pharmacy recall communications.
Where to find product info
FDA enforcement page or Boothwyn Pharmacy recall notices.
What timeline to expect
Refunds/replacements are determined by Boothwyn Pharmacy and may take weeks.
If the manufacturer is unresponsive
- File a complaint with consumer protection if Boothwyn Pharmacy is unresponsive.
- Contact your healthcare provider for guidance and potential alternatives.
How to prevent similar issues
- Verify drug potency alerts from manufacturers and pharmacies before dispensing.
- Ask pharmacists for lot numbers and expiration dates before accepting medications.
- Stay informed through FDA recall notices.
Documentation advice
Keep recall notices, lot/model numbers, purchase records, and correspondence with pharmacy and providers.
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Product Details
Brand: Boothwyn Pharmacy. Product: Semaglutide, 2.5 mg/mL injection, 2 mL. Quantity: 642 vials. Distribution: U.S. Nationwide. Recall Date: 2025-07-09. Status: ACTIVE. Models: 03202025@5, 03202025@6, 03202025@7, 03202025@8 BUD 07/18/2025.
Reported Incidents
No injuries or incidents have been reported.
Key Facts
- Subpotent drug (Class II)
- 全国回收 nationwide recall in the U.S.
- Recall status: ACTIVE
Browse More Recalls
Safety Guide
Not sure what to do next? Our guide walks you through the process step by step.
Read: What to Do When You Find a Recalled ProductGet Alerts for Health & Personal Care Recalls
Get instant alerts for recalls that affect you. Free forever.